Year: 2022

REGULATED INFORMATION Appointment to further integrate BioSenic’s both cell therapy and autoimmune disease platforms under the responsibility of a new CMO and cross-pollinate the experiences of both teams to accelerate clinical progression Mont-Saint-Guibert, Belgium, December 02, 2022, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the company specializing in serious autoimmune /inflammatory diseases and cell repair, today announces it has appointed Michel Wurm, MD, as interim Chief Medical Officer (CMO), responsible for the development of both of BioSenic’s cell therapy and autoimmune disease platforms. Michel Wurm replaces Anne Leselbaum as interim CMO and as an independent consultant. His appointment will commence with immediate effect. Both Michel and Anne worked and collaborated closely together alongside the medical and...

TORONTO, Dec. 02, 2022 (GLOBE NEWSWIRE) — Fairplay Ventures Inc. (“FPY” or the “Company”) (TSX-V: FPY.P) announces the resignation of Andriyko Herchak and appointment of Bruno Amadi to the Company’s board of directors. Mr. Herchak has tendered his resignation to pursue other business interests, and the Company is very grateful for his invaluable leadership, support and guidance. Mr. Amadi brings over 40 years of capital markets and corporate governance experience by virtue of his former position as Partner at KPMG LLP. Mr. Amadi held a Chartered Professional Accountant designation and a Fellowship Chartered Professional Accountant designation, and has been actively involved in over 90 mergers, acquisitions and diversiture transactions in Canada and internationally across a variety of industries. “We are very pleased to have Bruno...

TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) — Yubba Capital Corp. (TSXV: YUB.P) (“Yubba”) and Impact Housing Corporation (“IHC”) are pleased to announce that they have entered into a letter of intent dated December 1, 2022 (the “LOI”), pursuant to which Yubba and IHC will complete a transaction that will result in a reverse take-over of Yubba by IHC (the “Proposed Transaction”). The Proposed Transaction, if completed, will constitute Yubba’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). ABOUT IHC IHC is a Panamanian based real estate developer, incorporated under the laws of the Republic of Panama on February 15, 2017, that provides affordable housing supported by a longstanding subsidized government program with multiple product offerings. The principal business of IHC is...

CALGARY, Alberta, Dec. 01, 2022 (GLOBE NEWSWIRE) — Tornado Global Hydrovacs Ltd. (“Tornado” or the “Company”) (TSX-V: TGH; OTCQX: TGHLF) announces the voting results arising from its Annual General and Special Meeting of Shareholders held today. Voting Results The shareholders re-elected five directors to the board at the meeting: Guy Nelson, James Chui, George Tai, Chuyu Wu and Robert Marshall. The results of the vote on the election of the Board of Directors are as follows:  Votes In FavourGuy Nelson 63,245,961 100%James Chui 63,245,961 99.98%George Tai 63,245,961 99.99%Chuyu Wu 63,245,961 99.98%Robert Marshall 63,245,961 99.78%The 63 million proxies voted above represent approximately 48% of the total shares outstanding. Additionally, resolutions approving the following additional matters were passed at...

December 1, 2022 NEW YORK, NY, Dec. 01, 2022 (GLOBE NEWSWIRE) — On November 30, 2022, the stockholders of The Music Acquisition Corporation (“TMAC” or “the Company”) approved an amendment to TMAC’s amended and restated certificate of incorporation (the “Charter Amendment”) to allow TMAC to terminate early and redeem all of its outstanding Class A common stock (the “public shares”) prior to or on December 2, 2022. The Company filed the Charter Amendment with the Secretary of State of the State of Delaware on December 1, 2022. In connection with the approval and implementation of the Charter Amendment, the holders of 22,367,351 public shares, exercised their right to redeem their shares for cash at a redemption price of approximately $10.05 per share, for an aggregate redemption amount of approximately $224,698,655. The Company...

Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) — Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) is pleased to announce that it has entered into a credit agreement with The Bank of Nova Scotia (“Scotiabank”) providing for a senior secured revolving credit facility in an aggregate amount of up to US$35 million (the “Revolving Credit Facility”). The initial drawdown under the Revolving Credit Facility will be used to repay the Company’s existing syndicated facility with HSBC Bank Canada and Macquarie Bank Limited (the “Existing Facility”) which had US$32.6 million outstanding before repayment. The residual proceeds from the Revolving Credit Facility will be used for general corporate and working capital purposes....

Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results Plan to Meet with Regulatory Authorities to Determine Next StepsNEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive...

December 1, 2022 NEW YORK, NY, Dec. 01, 2022 (GLOBE NEWSWIRE) — On November 30, 2022, the stockholders of The Music Acquisition Corporation (“TMAC” or “the Company”) approved an amendment to TMAC’s amended and restated certificate of incorporation (the “Charter Amendment”) to allow TMAC to terminate early and redeem all of its outstanding Class A common stock (the “public shares”) prior to or on December 2, 2022. The Company filed the Charter Amendment with the Secretary of State of the State of Delaware on December 1, 2022. In connection with the approval and implementation of the Charter Amendment, the holders of 22,367,351 public shares, exercised their right to redeem their shares for cash at a redemption price of approximately $10.07 per share, for an aggregate redemption amount of approximately $225,342,749. The Company...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company’s lead investigational peptide drug conjugate (PDC) for the treatment of sortilin-expressing cancers. The Company plans to submit an amendment to its protocol to the U.S. Food and Drug Administration (FDA) for approval. Theratechnologies voluntarily made the decision to pause enrollment...